www.nytimes.com
From No Hope to a Potential Cure for a Deadly Blood Cancer
#MultipleMyeloma is an active hashtag on Bluesky. In the last 30 days, 15 people shared 41 posts with it — around 1 a day. Activity is down 43% versus the previous week, peaking on Sep 3 with 4 posts.
Tags most often used together with #MultipleMyeloma.
www.nytimes.com
From No Hope to a Potential Cure for a Deadly Blood Cancer
media.tenor.com
I'M Great! I'M Better Thangreat. I Am Good..Gif GIF
Alt: Joey says, "I'M Great! I'M Better Than great. I Am Good."
www.science.org
Bone marrow breakout lesions act as key sites for tumor-immune cell diversification in multiple myeloma
Single-cell and spatial multiomics analyses identify breakout lesions as a hotspot for tumor-immune interactions and diversification.
bit.ly
New Study Reveals a Fiber Diet May Delay a Type of Blood Cancer
Researchers from Memorial Sloan Kettering Cancer Center to present the latest advances in blood cancer during The American Society of Hematology 2024 annual meeting.
bit.ly
New Study Reveals a Fiber Diet May Delay a Type of Blood Cancer
Researchers from Memorial Sloan Kettering Cancer Center to present the latest advances in blood cancer during The American Society of Hematology 2024 annual meeting.
www.science.org
PSGL-1 is a phagocytosis checkpoint that enables tumor escape from macrophage clearance
PSGL-1 acts as a phagocytosis checkpoint to promote tumor immune escape through impeding LFA-1 activation in macrophages.
pharmatimes.com
NICE backs daratumumab quadruplet for transplant‑eligible myeloma - PharmaTimes
Guidance supports MRD‑guided treatment approach
📢 Webinar Update Our Smoldering Multiple Myeloma webinar with Shaji Kumar, MD and Adeel Khan, MD has been rescheduled following the passing of Robert A. Kyle, MD. We extend our condolences to his family and the myeloma community. Register: hemehub.org/live-webinars #MultipleMyeloma #HemeOnc
pharmaphorum.com
GSK wagers $750m on Chimagen multiple myeloma therapy
GSK has continued a drive to bulk up its pipeline, taking global rights to a T-cell engager for multiple myeloma, developed by China's Chimagen Bio.
www.postbulletin.com
Vyriad, Mayo Clinic begin clinical trial on new CAR-T treatment
Up to 40 patients with multiple myeloma will be enrolled in the Phase 1 clinical trial to test an emerging therapy: in vivo CAR-T.
Posts are pulled live from Bluesky and cached briefly. Posts with content labels are hidden.